$1.68
-0.06 (-3.17%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NGEN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 3 tracked-famous managers (MARSHALL WACE, LLP, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC) · FINRA short interest 9.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| NVG-291 in Spinal Cord Injury SubjectsNCT05965700ElectrophysiologicalRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: NVG-291 | Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury | 24 | 2025-12-31actual | 2026-06-15 |
| A Phase I Safety Study of NVG-291 in Healthy AdultsNCT05308953Adverse EventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: NVG-291 · Other: Placebo | Spinal Cord Injury | 74 | 2023-06-04actual | 2024-01-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19